1[1]Otsuji E. Advances in the treatment of gastric carcinoma[J]. Cancer, 1998,82:1233～1237.
2[2]Takahashi T, Hagiwara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis:intraperitioneal chemotherapy with Mitomycin C bound to activated carbon particles[J].Surg, 1995,4:565～569.
3[3]Hagiwara A. Mitomycin C absorbed to activated carbon particles as a new drug dosage form for cancer chemotherapy [ in Japanese]Akita[J]. J Med, 1983,10:187～229.
4[4]Hagiwara A, Takahashi T, Kojima C, et al. Prophytaxis with carbon absorbed Mitomycin against peritioneal recurrence of gastric cancer[J]. Lancet, 1992,339:629～631.
5[5]Hagiwara A, Takahashi T, Ueda T, et al. Toxicity and pathological effects of a new dosage form of Mitomycin C for carcinomatous peritoneal[J ]. Anticancer Res, 1987,7:105～108.
6[6]HagiwaraA, TakahashiT, LeeR, et al. Enhanced chemotherapeutic efficacy on carcinomatous peritonitis using a new dos age form in animal experiments[J]. Anticancer Res, 1987, 7: 167～170.
7[7]Hagiwara A Hirata Y, Takahashi T. A pilot study of fiberscopy guided local injection of anti-cancer drugs bound to carbon particals for control of rectal cancer[J]. Anticancer Drugs, 1998,9(4): 363～367.
8[8]HagiwaraA, TakahashiT, Kojima O, et al. Endoscopiclocalinjection of a new drug-delivery form of Peplomycin for superficial esophageal cancer: a pilot study[J]. Gastroenterology, 1993, 104(4):1037～1043.
